ELIXA trial shows CV safety of Lixisenatide
In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the ...
Aug 31, 2015
0
10